Formoterol Glycopyrrolate Rotacap Franchise in Ahmedabad

Formoterol 12mcg + Glycopyrrolate 12.5mcg Rota Capsule Supplier in Mumbai

COPD Therapy Capsule Distributor in Delhi

Bronchodilator Rotacap Manufacturer in Bangalore

Respiratory Care Rotacap Stockist in Hyderabad
Formoterol Glycopyrrolate Rota Capsule Exporter in Chandigarh

Home/Products /glycopyrrolate-12-point-50-mcg-formoterol-12-mcg-rota-cap

Flutialfa G 12 Rota Capsule

Composition : Formoterol (12mcg) + Glycopyrrolate (12.5mcg) Rota Capsule

Dosage Form : Rota cap

Packaging Type : in a Bottle

Packaging : 30 Capsules

Price : ₹1/-

Contact For Business Query

Formoterol 12mcg + Glycopyrrolate 12.5mcg rota capsule is a dual-action bronchodilator formulation used for the effective management of chronic obstructive pulmonary disease (COPD) and bronchospasm.

Formoterol provides long-acting beta-2 adrenergic bronchodilation, relaxing airway smooth muscles, while Glycopyrrolate acts as a long-acting muscarinic antagonist, reducing airway constriction and improving airflow.

This rotacap is commonly prescribed for maintenance therapy in COPD, chronic bronchitis, and emphysema, helping reduce breathlessness, wheezing, and the frequency of exacerbations.

With clinically proven efficacy, dual-mechanism action, and convenient once-daily dosing, this formulation strengthens a respiratory therapy product portfolio and supports consistent patient demand for pulmonary care.

Read More

About the Product

Formoterol 12mcg + Glycopyrrolate 12.5mcg rota capsule is a dual-action bronchodilator formulation used for the effective management of chronic obstructive pulmonary disease (COPD) and bronchospasm.

Formoterol provides long-acting beta-2 adrenergic bronchodilation, relaxing airway smooth muscles, while Glycopyrrolate acts as a long-acting muscarinic antagonist, reducing airway constriction and improving airflow.

This rotacap is commonly prescribed for maintenance therapy in COPD, chronic bronchitis, and emphysema, helping reduce breathlessness, wheezing, and the frequency of exacerbations.

With clinically proven efficacy, dual-mechanism action, and convenient once-daily dosing, this formulation strengthens a respiratory therapy product portfolio and supports consistent patient demand for pulmonary care.

Common side effects may include dry mouth, throat irritation, cough, tremors, headache, or mild dizziness. Rarely, urinary retention, palpitations, or cardiovascular effects may occur in sensitive patients.

Flutialfa G 12 Rota Capsule is indicated for the maintenance treatment of COPD, including chronic bronchitis and emphysema. It helps in controlling symptoms, improving lung function, and reducing exacerbations, as prescribed by a healthcare professional.

For inhalation use only. Use under strict medical supervision. Not intended for acute bronchospasm relief. Follow proper inhalation technique and clean the inhaler as directed.

Store below 25°C in a cool, dry place. Protect from direct sunlight and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation

@2024 | copy rights by Cafoli